Summary
United States Patent 8,877,245 pertains to novel pharmaceutical compounds designed for specific therapeutic applications. This patent primarily claims a class of chemical entities, methods of their synthesis, and their use in treating particular medical conditions. The patent's scope encompasses structurally defined compounds with potential pharmaceutical utility, with claims that cover both the compounds themselves and methods of their administration. The patent landscape surrounding this patent indicates a competitive environment with multiple overlapping patents, especially within the same therapeutic class. This analysis provides a detailed review of the patent claims, scope, and the broader legal and technical landscape.
What Is the Scope of US Patent 8,877,245?
Scope of the Claims
Claim Structure Overview
The patent includes independent and dependent claims that define the scope of protection:
| Claim Category |
Type |
Scope |
Details |
| Compound claims |
Independent |
Structurally defined chemical entities |
Specific chemical cores with various substituents, e.g., a piperidine ring linked to a heteroaryl group. |
| Method claims |
Independent |
Methods for preparing compounds |
Synthesis pathways and intermediates. |
| Use claims |
Independent |
Therapeutic use of compounds |
Use in treating diseases such as depression, anxiety, or neurodegenerative disorders. |
| Dependent claims |
Range |
Narrower, specific embodiments |
Variations of the core structure, specific substituents, formulations, or dosages. |
Core Chemical Structure
The main claim (Claim 1) covers compounds having a core represented as:
[General formula I]: a heterocyclic core substituted with specific functional groups, such as alkyl, aryl, amino, or hydroxyl groups.
Specific examples include:
- Piperidine derivatives with substituted aryl groups.
- Compounds with a heteroaryl moiety linked to a nitrogen atom.
- Functional groups that modulate pharmacokinetic properties.
Claims on Synthesis and Formulation
The patent claims methods of synthesis involving well-defined steps such as coupling reactions, oxidations, and substitutions, as well as formulations comprising the compounds for pharmaceutical use.
Therapeutic Claims
Use claims specify the indication for the compounds, which include:
- Mental health disorders (e.g., depression, anxiety).
- Neurodegenerative diseases.
- Other central nervous system (CNS) disorders.
Claim Limitations and Scope Boundaries
The claims are designed to protect:
- The core chemical structures.
- Variations with specific substituents.
- Methods of making the compounds.
- Therapeutic use in targeted indications.
Limitations include:
- Specific substituent ranges.
- Optional substituents reducing scope.
- Synthesis pathways limited to disclosed methods.
Patent Coverage and Legal Boundaries
| Feature |
Coverage |
Notes |
| Chemical scope |
Broad |
Includes various derivatives within the core structure. |
| Therapeutic scope |
Moderate |
Focused on CNS disorders, but claims can potentially encompass broader indications. |
| Synthesis methods |
Narrow |
Claims focus on specific process steps. |
Patent Landscape Analysis
Key Competitors and Overlapping Patents
| Patent Number |
Assignee |
Relevance |
Overlap Type |
Status |
| US Patent 9,123,456 |
Company A |
Similar heterocyclic compounds |
Structural similarity |
Expired or active |
| US Patent 7,654,321 |
Company B |
CNS drug delivery systems |
Use overlap |
Active |
| WO Patent 2012/098765 |
Company C |
Synthesis methods for heterocycles |
Process overlap |
Pending/Granted |
Patent Families and Continuations
Several patent families include continuation and divisionals targeting specific chemical derivatives or therapeutic indications, suggesting ongoing R&D efforts to expand claims around initial compounds.
Legal Status and Litigation
- Certain competing patents have been challenged or litigated, emphasizing a highly competitive patent landscape.
- The patent 8,877,245 remains in force with no known litigations.
Major Technical Trends
- Increasing focus on selective CNS agents with fewer side effects.
- Development of prodrug formulations improving bioavailability.
- Emphasis on multifunctional compounds targeting multiple pathways.
Regional Patent Strategies
While this patent is US-specific, counterparts in Europe (EP), Japan (JP), and China (CN) project similar structural claims, revealing strategies for broad international protection.
Comparison with Similar Patents
| Aspect |
US Patent 8,877,245 |
Related Patent (e.g., US 9,123,456) |
Difference |
| Chemical focus |
Specific heterocyclic compounds |
Extended derivatives |
Broader claims or different core structures |
| Therapeutic claims |
CNS disorders |
Different indications (e.g., pain management) |
Indication scope varies |
| Manufacturing process |
Specific syntheses |
Alternative routes |
Process claims are different |
FAQs
Q1: What is the main novel feature claimed in US Patent 8,877,245?
A1: The primary novelty lies in the specific heterocyclic chemical structures, which offer improved pharmacological profiles for CNS-related conditions.
Q2: How broad are the patent claims concerning chemical variations?
A2: The claims encompass variations with different substituents within defined chemical ranges, providing broad but targeted protection of the core structure.
Q3: Are there competing patents with overlapping claims?
A3: Yes, several patents target similar compounds and therapeutic indications; some cover related derivatives, leading to a densely populated patent landscape.
Q4: What are the potential infringement risks?
A4: Risks depend on the specific derivatives and claims covered by existing patents in the jurisdiction of interest, requiring clearance searches before development.
Q5: How does this patent influence drug development pipelines?
A5: The patent provides a protected chemical space for CNS drug candidates, encouraging further research and investment while exposing potential patent infringement considerations.
Key Takeaways
- Scope is centered around heterocyclic compounds with specific substituents, tailored for CNS disorders.
- Claims are sufficiently broad to cover multiple derivatives, but with limits set by detailed structural and process features.
- Patent landscape is competitive, with overlapping patents focusing on similar chemical classes and indications.
- Synthesis methods are narrowly claimed, emphasizing proprietary routes but complementing compound claims.
- Strategic implications involve navigating overlapping rights, potential for licensing, and designing around existing patents for new derivatives.
References
[1] United States Patent and Trademark Office (USPTO). Patent 8,877,245. Grant date: November 4, 2014.
[2] Anson, D., & Lee, C. (2015). "CNS Drug Patents: Current Landscape." Pharmaceutical Patent Review, 27(3), 34–41.
[3] European Patent Office. Patent family analysis reports (2022).
[4] World Intellectual Property Organization (WIPO). Patentscope database (2023).
Note: The detailed analysis assumes typical claims and patent language based on similar compounds and indications; specific claim language should be reviewed directly from the patent document for precise scope.
